** U.S.-listed shares of Atai Life Sciences 9VC.DE, ATAI.O rise 25% to $2.71 premarket
** Atai and Oxford-based firm Beckley Psytech say their experimental depression drug, BPL-003, met the main goals in a mid-stage study
** Both 8 mg and 12 mg single doses of the drug significantly reduced depressive symptoms compared to a low-dose control at all time points through eight weeks, cos say
** Firms say the trial data support advancing the 8 mg dose into late-stage trial, pending regulatory discussions
** Last month, Atai announced a $390 mln merger with Beckley Psytech to create a combined psychedelic mental health therapy firm
** As of last close, ATAI up 64.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.